208 related articles for article (PubMed ID: 22869577)
1. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
McPhee F; Sheaffer AK; Friborg J; Hernandez D; Falk P; Zhai G; Levine S; Chaniewski S; Yu F; Barry D; Chen C; Lee MS; Mosure K; Sun LQ; Sinz M; Meanwell NA; Colonno RJ; Knipe J; Scola P
Antimicrob Agents Chemother; 2012 Oct; 56(10):5387-96. PubMed ID: 22869577
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
3. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
McPhee F; Friborg J; Levine S; Chen C; Falk P; Yu F; Hernandez D; Lee MS; Chaniewski S; Sheaffer AK; Pasquinelli C
Antimicrob Agents Chemother; 2012 Jul; 56(7):3670-81. PubMed ID: 22508297
[TBL] [Abstract][Full Text] [Related]
4. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
[TBL] [Abstract][Full Text] [Related]
5. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
Mosure KW; Knipe JO; Browning M; Arora V; Shu YZ; Phillip T; Mcphee F; Scola P; Balakrishnan A; Soars MG; Santone K; Sinz M
J Pharm Sci; 2015 Sep; 104(9):2813-23. PubMed ID: 25631585
[TBL] [Abstract][Full Text] [Related]
8. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
Pasquinelli C; McPhee F; Eley T; Villegas C; Sandy K; Sheridan P; Persson A; Huang SP; Hernandez D; Sheaffer AK; Scola P; Marbury T; Lawitz E; Goldwater R; Rodriguez-Torres M; Demicco M; Wright D; Charlton M; Kraft WK; Lopez-Talavera JC; Grasela DM
Antimicrob Agents Chemother; 2012 Apr; 56(4):1838-44. PubMed ID: 22290978
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
10. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
[TBL] [Abstract][Full Text] [Related]
11. Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment.
Inoue J; Kanno A; Wakui Y; Miura M; Kobayashi T; Morosawa T; Kogure T; Kakazu E; Ninomiya M; Fujisaka Y; Umetsu T; Takai S; Nakamura T; Shimosegawa T
Tohoku J Exp Med; 2017 Jan; 241(1):21-28. PubMed ID: 28049871
[TBL] [Abstract][Full Text] [Related]
12. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Zhai PB; Qing J; Li B; Zhang LQ; Ma L; Chen L
Acta Pharmacol Sin; 2018 Nov; 39(11):1746-1752. PubMed ID: 29930277
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
[TBL] [Abstract][Full Text] [Related]
14. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
Lin TI; Lenz O; Fanning G; Verbinnen T; Delouvroy F; Scholliers A; Vermeiren K; Rosenquist A; Edlund M; Samuelsson B; Vrang L; de Kock H; Wigerinck P; Raboisson P; Simmen K
Antimicrob Agents Chemother; 2009 Apr; 53(4):1377-85. PubMed ID: 19171797
[TBL] [Abstract][Full Text] [Related]
16. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Kan H; Hiraga N; Imamura M; Hayes CN; Uchida T; Miyaki E; Tsuge M; Abe H; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antivir Ther; 2016; 21(4):307-15. PubMed ID: 26562322
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.
Yang H; Yang C; Wang Y; Rhodes G; Robinson M; Cheng G; Qi X; Mo H; Tian Y; Pakdaman R; Sheng XC; Kim CU; Delaney WE
Antivir Ther; 2017; 22(5):413-420. PubMed ID: 28106531
[TBL] [Abstract][Full Text] [Related]
18. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
[TBL] [Abstract][Full Text] [Related]
19. Asunaprevir for hepatitis C: a safety evaluation.
Gentile I; Zappulo E; Buonomo AR; Scotto R; Borgia G
Expert Opin Drug Saf; 2015 Oct; 14(10):1631-46. PubMed ID: 26329454
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
